

## Fondaparinux (Arixtra) Anti-Xa – Cessation of Testing

Date: October 4th, 2023

Effective Date: November 1st, 2023

As of November 1<sup>st</sup>, 2023, fondaparinux (Arixtra) anti-Xa testing at UR Medicine Laboratories will be discontinued. Chromogenic fondaparinux testing is available through reference laboratories with a turnaround time of 2-3 days. Specimen requirements will remain the same; 1 full blue-top (sodium citrate) tube. To test peak effect, specimen collection is recommended at 3 hours' post-injection.

Testing for low molecular weight heparin and unfractionated heparin are not affected by this change and will remain available 24/7 for Strong Memorial Hospital inpatients.

Link for more test information:

## Labcorp Fondaparinux Anti-Xa

If you have any questions please contact Geoffrey Harris, Chief Supervisor for Hematology & Chemistry Laboratories at Strong Memorial Hospital, at (585) 275-2435 or <a href="mailto:Geoffrey\_Harris@urmc.rochester.edu">Geoffrey\_Harris@urmc.rochester.edu</a>, or Dr. Refaai at any of the below methods listed.

From: Majed Refaai, MD

Professor of Pathology & Laboratory Medicine Thrombosis/Hemostasis Laboratory Director University of Rochester Medical Center

Phone: (585) 276-3927

Email: Majed\_Refaai@urmc.rochester.edu